Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. [electronic resource]
Producer: 20060509Description: 1831-8 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- Cisplatin -- administration & dosage
- Disease Progression
- Docetaxel
- Female
- Humans
- Infusions, Intravenous
- Middle Aged
- Receptor, ErbB-2 -- analysis
- Survival Analysis
- Taxoids -- administration & dosage
- Trastuzumab
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.